Antimicrobial susceptibility rates for clinical isolates of
Pseudomonas aeruginosa in an acute-care community hospital between 2008 and 2010 were analyzed in order to promote appropriate use of antimicrobial agents and to prevent the emergence of multiple drug resistance
P. aeruginosa (MDRP). A total of 1343 strains isolated from both inpatients and outpatients were determined for their susceptibility to antimicrobial agents, including piperacillin (PIPC), ceftazidime (CAZ), cefozopran (CZOP), imipenem/cilastatin (IPM/CS), meropenem (MEPM), ciprofloxacin (CPFX), amikacin (AMK), and gentamicin (GM). Of 1343 isolates tested, the resistance rates decreased from 6.4% to 3.3% between 2008 and 2010 for IPM/CS; similarly, 2.7% to 1.4% for MEPM, and 13.4% to 5.5% for CPFX. The non-susceptibility rates for aminoglycosides ranged between 0.4% and 2.2% for AMK, and between 1.7% and 4.0% for GM. On the other hand, the overall rates of non-susceptibility for PIPC, CAZ, and CZOP gradually increased during the same surveillance period. Only one episode of MDRP isolation was documented in a patient referred from another hospital. Diminished rates of resistance of
P. aeruginosa to carbapenems could be partly ascribed to reduced consumption of carbapenems. Combined efforts of monitoring antimicrobial resistance, infection control activity, and shortening hospital stay are helpful to promote optimal use of antimicrobial agents.
View full abstract